The DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
IDH1 and IDH2 Mutations in Gliomas
Open accessAbstract
BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas). METHODS: We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors. The enzymatic activity of the proteins that were produced from normal and mutant IDH1 and IDH2 genes was determined in cultured glioma cells that were transfected with these genes. RESULTS: We identified mutations that affected amino acid 132 of IDH1 in more than 70% of WHO grade II and III astrocytomas and oligodendrogliomas and in glioblastomas that developed from these lower-grade lesions. Tumors without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene. Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes. Each of four tested IDH1 and IDH2 mutations reduced the enzymatic activity of the encoded protein. CONCLUSIONS: Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yan et al., 2009
In the citing paper
“Both IDH1 R132 and IDH2 R172 mutants lack the wild-type enzyme’s ability to convert isocitrate to α-ketoglutarate”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Yan et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Yan et al., 2009
In the citing paper
“This is consistent with data presented here that IDH1-mutated and IDH2-mutated AML samples typically do not harbor other known mutations associated with AML, as well as a prior report that IDH-mutated gliomas often lack other mutations that are commonly acquired early in glioma pathogenesis (Yan et al., 2009).”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Yan et al., 2009
In the citing paper
“Monoallelic mutation of the same residue in IDH1, or the analogous residue in the related enzyme IDH2, is a common feature of gliomas as more than 80% of indolent gliomas harbor such a mutation (28, 29).”
From Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation (2009) · cites this paper as [29]
In the citing paper
“The IDH genes (IDH1 and IDH2) encode isocitrate dehydrogenases, and mutations in these genes are among the most frequent found in diffuse gliomas118,119.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [119]
In the citing paper
“These “oncohistones” are found almost exclusively in pHGG and are mutually exclusive with the recurrent mutations in isocitrate dehydrogenase enzymes (IDH) identified in young adult gliomas”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Yan et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [171]
In the citing paper
“a small fraction of gliomas lacking IDH1 mutations were known to harbor mutations at IDH2 R172, the analogous residue to IDH1 R132 (Yan et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Yan et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Yan et al., 2009
In the citing paper
“the presence of IDH1/2 mutations in gliomas is associated with both lower histological grade and a slower rate of disease progression”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Yan et al., 2009
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“The elevated levels of D-2-HG was associated with increased DNA methylation levels at the Foxp3 locus, the master transcription factor driving iTreg differentiation, resulting in its repression143.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“Inhibition of GOT1 by aminooxyacetic acid (AOAA), which decreases D-2-HG levels, promoted expression Foxp3 and the differentiation of TH17 cells to iTregs143.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“On the other hand, induced regulatory T (iTreg) cells, also derived from naïve CD4+ T cells, do not require HIF-1α143,146.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“T-helper 17 (TH17) cells, derived from naïve CD4+ T cells, are one such subset that rely heavily on a switch from OXPHOS to glycolysis, a process that requires the activation of HIF-1α and induction of RORγt143,146.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“Lastly, AOAA ameliorated disease progression in EAE, a disease in which TH17 cells mediate pathology143.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“Interestingly, Xu and colleagues (2017) observed increased levels in of D-2-HG in TH17 cells, when compared to iTreg cells143.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
In the citing paper
“Mechanistically, D-2-HG production was driven by the conversion of glutamate to α-KG by the aspartate aminotransferase GOT1.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
PHILLIPS, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,197
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Self-citationMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
Self-citationMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Flagged first, then by citations
2 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press, 2000:45-51.
- Ueki K, 1996, Cancer Res, 56, 150
- Weber RG, 1996, Oncogene, 13, 983
- Reifenberger J, 1994, Am J Pathol, 145, 1175
Cited by
Sorted by citations
Items 501–600 of 1,012
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
Metabolic coordination of cell fate by α-ketoglutarate-dependent dioxygenases
Baksh, S. C., & Finley, L. W. S. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.010 · Cited by 165
Mitochondrial pathology: stress signals from the energy factory
Raimundo, N. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.005 · Cited by 165
Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 171
Paech, D., Windschuh, J., Oberhollenzer, J., Dreher, C., Sahm, F., Meissner, J., Goerke, S., Schuenke, P., Zaiß, M., Regnery, S., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy073 · Cited by 166
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Yang, P., Zhang, W., Wang, Y., Peng, X., Chen, B., Qiu, X., Li, G., Li, S., Wu, C., Yao, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5683 · Cited by 170
Anti-angiogenic therapy for high-grade glioma
Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J. R., & Khasraw, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008218.pub4 · Cited by 168
Understanding the central role of citrate in the metabolism of cancer cells
Icard, P., Poulain, L., & Lincet, H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.007 · Cited by 167
Villani, A., Greer, M. C., Kalish, J. M., Nakagawara, A., Nathanson, K. L., Pajtler, K. W., Pfister, S. M., Walsh, M. F., Wasserman, J. D., Zelley, K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0631 · Cited by 167
Targeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 164
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 169
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.64 · Cited by 162
Self-citationCaravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 162
Zhang, P., Qin, X., Liu, L., Li, S., & Dong, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.562798 · Cited by 169
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Targeting MTHFD2 in acute myeloid leukemia
Pikman, Y., Puissant, A., Alexe, G., Furman, A. A., Chen, L. M., Frumm, S. M., Ross, L. S., Fenouille, N., Bassil, C. F., Lewis, C. A., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151574 · Cited by 157
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update
Whitfield, B. T., & Huse, J. T. (2022) · Brain Pathology · doi:10.1111/bpa.13062 · Cited by 172
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162
Surgical resection of malignant gliomas—role in optimizing patient outcome
Eyüpoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.279 · Cited by 166
Immunotherapy for Brain Tumors
Sampson, J. H., Maus, M. V., & June, C. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8089 · Cited by 156
Dissecting and rebuilding the glioblastoma microenvironment with engineered materials
Wolf, K. J., Chen, J., Coombes, J. D., Aghi, M. K., & Kumar, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0135-y · Cited by 164
Horbinski, C., Kofler, J., Kelly, L. M., MURDOCH, G. H., & Nikiforova, M. N. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c391be · Cited by 155
Han, M., Wang, S., Fritah, S., Wang, X., Zhou, W., Yang, N., Ni, S., Huang, B., Chen, A., Li, G., et al. (2019) · Brain · doi:10.1093/brain/awz406 · Cited by 158
Developing dietary interventions as therapy for cancer
Taylor, S. R., Falcone, J. N., Cantley, L. C., & Goncalves, M. D. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00485-y · Cited by 168
Induction of sarcomas by mutant IDH2Preprint
Lü, C., Venneti, S., Akalin, A., Fang, F., Ward, P. S., Dematteo, R. G., Intlekofer, A. M., Chen, C., Ye, J., Hameed, M., et al. (2013) · Genes & Development · doi:10.1101/gad.226753.113 · Cited by 162
Vigneswaran, K., Neill, S. G., & Hadjipanayis, C. G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.57 · Cited by 157
Biomarkers and therapeutic advances in glioblastoma multiforme
Sasmita, A. O., Wong, Y. P., & Ling, A. P. K. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12756 · Cited by 167
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Kang, H., Fan, J., Lin, R., Elf, S., Ji, Q., Zhao, L., Jin, L., Seo, J. H., Shan, C., Arbiser, J. L., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.037 · Cited by 162
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics
Lehtonen, H. J. (2011) · Familial Cancer · doi:10.1007/s10689-011-9428-z · Cited by 156
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 158
Self-citationRole of Metabolic Reprogramming in Epithelial–Mesenchymal Transition (EMT)
Kang, H., Kim, H., Lee, S., Youn, H., & Youn, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082042 · Cited by 157
Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 158
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Yan, H., Bigner, D. D., Velculescu, V. E., & Parsons, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2650 · Cited by 156
Self-citationLi, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 158
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
The Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
Andronesi, O. C., Loebel, F., Bogner, W., Marjańska, M., Heiden, M. G. V., Iafrate, A. J., Dietrich, J., Batchelor, T. T., Gerstner, E. R., Kaelin, W. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0656 · Cited by 153
Management of Low-Grade Glioma
Pouratian, N., & Schiff, D. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0105-7 · Cited by 153
Kawaguchi, T., Sonoda, Y., Shibahara, I., Saito, R., Kanamori, M., Kumabe, T., & Tominaga, T. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2201-2 · Cited by 154
Park, Y. W., Han, K., Ahn, S. S., Bae, S., Choi, Y. S., Chang, J. H., Kim, S. H., Kang, S., & Lee, S. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5421 · Cited by 155
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC
Khattar, E., & Tergaonkar, V. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00001 · Cited by 154
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma
Lee, D., Xu, M., Chiu, D. K., Lai, R. K., Tse, A. P., Li, L. L., Law, C., Tsang, F. H., Wei, L. L., Chan, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90253 · Cited by 153
Thom, M., Toma, A. K., An, S., Martinian, L., Hadjivassiliou, G., Ratilal, B. O., Dean, A. F., McEvoy, A. W., Sisodiya, S. M., & Brandner, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182302475 · Cited by 151
Genetic insights into OXPHOS defect and its role in cancer
Chandra, D., & Singh, K. K. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.023 · Cited by 155
Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Mitochondria and Cancer: A Growing Role in Apoptosis, Cancer Cell Metabolism and Dedifferentiation
Scatena, R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_13 · Cited by 152
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Makishima, H., Jankowska, A. M., McDevitt, M. A., O’Keefe, C. L., Dujardin, S., Cazzolli, H., Przychodzen, B. P., Prince, C. J., Nicoll, J. M., Harish, S., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292433 · Cited by 155
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 157
Sanai, N., Chang, S. M., & Berger, M. S. (2011) · Journal of neurosurgery · doi:10.3171/2011.7.jns10238 · Cited by 150
Leu, K., Ott, G. A., Lai, A., Nghiemphu, P. L., Pope, W. B., Yong, W. H., Liau, L. M., Cloughesy, T. F., & Ellingson, B. M. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2506-9 · Cited by 149
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Daniel, P. M., Sabri, S., Chaddad, A., Meehan, B., Jean‐Claude, B. J., Rak, J. W., & Abdulkarim, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00041 · Cited by 152
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 153
Sherriff, J., Tamangani, J., Senthil, L., Cruickshank, G., Spooner, D. A., Jones, B., Brookes, C. L., & Sanghera, P. (2013) · British Journal of Radiology · doi:10.1259/bjr.20120414 · Cited by 148
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 151
Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy
Gajjar, A. J., Pfister, S. M., Taylor, M. D., & Gilbertson, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0833 · Cited by 150
Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders
Burrage, L. C., Nagamani, S. C. S., Campeau, P. M., & Lee, B. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu123 · Cited by 147
Wefel, J. S., Noll, K. R., Rao, G., & Cahill, D. P. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now165 · Cited by 147
Sun, Q., Chen, Y., Liang, C., Zhao, Y., Lv, X., Zou, Y., Yan, K., Zheng, H., Liang, D., & Li, Z. (2021) · Radiology · doi:10.1148/radiol.2021203281 · Cited by 146
Emerging Insights into Barriers to Effective Brain Tumor Therapeutics
Woodworth, G. F., Dunn, G. P., Nance, E. A., Hanes, J. S., & Brem, H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00126 · Cited by 153
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
Frontline treatment of acute myeloid leukemia in adults
Tamamyan, G., Kadia, T. M., Ravandi, F., Borthakur, G. M., Cortes, J. E., Jabbour, E. J., Daver, N. G., Ohanian, M. N., Kantarjian, H. M., & Konopleva, M. Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.004 · Cited by 151
Zhang, Y. W., Wang, Z., Xie, W., Cai, Y., Xia, L., Easwaran, H., Luo, J., Yen, R.-W. C., Li, Y., & Baylin, S. B. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.013 · Cited by 148
Fack, F., Tardito, S., Hochart, G., Oudin, A., Zheng, L., Fritah, S., Golebiewska, A., Nazarov, P. V., Bernard, A., Hau, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707729 · Cited by 148
Treatment of glioblastoma in adults
Wick, W., Osswald, M., Wick, A., & Winkler, F. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418790452 · Cited by 153
The molecular feature of macrophages in tumor immune microenvironment of glioma patients
Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 150
Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data
Ding, J., Bashashati, A., Roth, A. J. L., Oloumi, A., Tse, K., Zeng, T., Haffari, G., Hirst, M., Marra, M. A., Condon, A., et al. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr629 · Cited by 145
2016 World Health Organization Classification of Central Nervous System Tumors
Wen, P. Y., & Huse, J. T. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000536 · Cited by 143
The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells
Prochownik, E. V., & Wang, H. (2021) · Cells · doi:10.3390/cells10040762 · Cited by 150
Reifenberger, G., Weber, R. G., Riehmer, V., Kaulich, K., Willscher, E., Loeffler‐Wirth, H., Gietzelt, J., Hentschel, B., Westphal, M., Simon, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28836 · Cited by 141
Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
Kalpathy–Cramer, J., Gerstner, E. R., Emblem, K. E., Andronesi, O. C., & Rosen, B. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0383 · Cited by 149
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers
Geiger, T., Madden, S. F., Gallagher, W. M., Cox, J., & Mann, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3711 · Cited by 144
Gorovets, D. J., Kannan, K. S., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., Pentsova, E. I., Heguy, A., Jhanwar, S. C., Mellinghoff, I. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2977 · Cited by 145
Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas
Götze, S., Wolter, M., Reifenberger, G., Müller, O., & Sievers, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24981 · Cited by 147
Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research
Lasocki, A., & Gaillard, F. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6025 · Cited by 144
Kant, S., Kesarwani, P., Prabhu, A. H., Graham, S. F., Buelow, K. L., Nakano, I., & Chinnaiyan, P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2449-5 · Cited by 145
Marie, S. K. N., & Oba‐Shinjo, S. M. (2011) · Clinics · doi:10.1590/s1807-59322011001300005 · Cited by 148
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
Nam, J. Y., & de Groot, J. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.025536 · Cited by 147
Andronesi, O. C., Arrillaga‐Romany, I., Ly, I., Bogner, W., Ratai, E., Reitz, K., Iafrate, A. J., Dietrich, J., Gerstner, E. R., Chi, A. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03905-6 · Cited by 141
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 147
Update on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 146
Wick, W., Dettmer, S., Berberich, A., Keßler, T., Karapanagiotou‐Schenkel, I., Wick, A., Winkler, F., Pfaff, E., Brors, B., Debus, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy161 · Cited by 145
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Yu, D., Liu, Y., Zhou, Y., Ruiz‐Rodado, V., Larion, M., Xu, G., & Yang, C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913633117 · Cited by 142
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
Leeper, H. E., Caron, A. A., Decker, P. A., Jenkins, R. B., Lachance, D. H., & Giannini, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4497 · Cited by 146
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Sonoda, Y., Kumabe, T., Nakamura, T., Saito, R., Kanamori, M., Yamashita, Y., Suzuki, H., & Tominaga, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01270.x · Cited by 140
Salminen, A., Kauppinen, A., Hiltunen, M. O., & Kaarniranta, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.05.004 · Cited by 145
IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148
Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification
Blümcke, I., Aronica, E., Becker, A. J., Capper, D., Coras, R., Honavar, M., Jacques, T. S., Kobow, K., Miyata, H., Mühlebner, A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.173 · Cited by 139
Jenkins, R. B., Xiao, Y., Sicotte, H., Decker, P. A., Kollmeyer, T. M., Hansen, H. M., Kosel, M., Zheng, S., Walsh, K. M., Rice, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2388 · Cited by 140
Non-invasive in vivo assessment of IDH1 mutational status in glioma
Chaumeil, M. M., Larson, P. E. Z., Yoshihara, H. A. I., Danforth, O. M., Vigneron, D. B., Nelson, S. J., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2013) · Nature Communications · doi:10.1038/ncomms3429 · Cited by 142
Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 138
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Garber, S. T., Hashimoto, Y., Weathers, S.-P. S., Xiu, J., Gatalica, Z., Verhaak, R. G. W., Zhou, S., Fuller, G. N., Khasraw, M., de Groot, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now132 · Cited by 140
Metadata
- Authors
- Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., & Bigner, D. D.
- Affiliations
- Duke University (US)
- Howard Hughes Medical Institute (US)
- Pediatric Brain Tumor Foundation (US)
- United States Food and Drug Administration (US)
- Johns Hopkins University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-02-19
- Volume
- 360
- Issue
- 8
- Pages
- 765-773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2820383
- OpenAlex
- W2126817554
- Cited by
- 5,847
- References
- 30
- Citations by year
- 2026: 168 · 2025: 256 · 2024: 330 · 2023: 367 · 2022: 397 · 2021: 481 · 2020: 496 · 2019: 374 · 2018: 398 · 2017: 369 · 2016: 296 · 2015: 340 · 2014: 350 · 2013: 336 · 2012: 322
- FWCI
- 139.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15, 5p50ns020023-30)
- University of California, Los Angeles
- National Cancer Institute (5R37 CA11898, 2 P30 CA 14236, R37CA011898, R01CA118822, CA 57345, R01-CA121113, CA-121113, CA43460, R37CA043460, R01CA057345, R37CA11898-34, P50CA108786, R01CA140316, P50CA062924, R37CA057345, P30CA014236)
- National Institute of Neurological Disorders and Stroke (P50-NS020023, NS20023-21, 5P50NS20023)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IDH1 mutation, IDH2 mutation, isocitrate dehydrogenase, glioma, glioblastoma, astrocytoma, oligodendroglioma, secondary glioblastoma, NADP-isocitrate dehydrogenase, enzyme activity, patient outcomes
- MeSH terms
- Adult, Astrocytoma, Brain Neoplasms, DNA Mutational Analysis, Glioblastoma, Glioma, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasms, Oligodendroglioma, Tumor Cells, Cultured, Disease Progression, Kaplan-Meier Estimate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
